Incyte (WBO:INCY) Beneish M-Score: -2.48 (As of Jun. 26, 2026)


WBO:INCY Incyte Corp WBO:INCY
88 GF Score
Price €70.36
GF Value €65.02
! 3 Warning Signs
View Full Analysis

What is Incyte Beneish M-Score?

Incyte WBO:INCY 88 Beneish M-Score is -2.48 as of Jun. 26, 2026. GuruFocus rates WBO:INCY with a GF Score™ of 88/100 and a GF Value™ of €65.02. The stock has 3 warning signs investors should review. Among 831 Biotechnology companies, Incyte ranks better than 54.39% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.48 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Incyte's Beneish M-Score or its related term are showing as below:

WBO:INCY' s Beneish M-Score Range Over the Past 10 Years
Min: -3.1   Med: -2.53   Max: 0.41
Current: -2.48

During the past 13 years, the highest Beneish M-Score of Incyte was 0.41. The lowest was -3.10. And the median was -2.53.


Incyte Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Incyte's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Beneish M-Score Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.94 -3.03 -2.21 -2.77 -2.58

Incyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.75 -2.58 -2.56 -2.58 -2.48

WBO:INCY vs MRNA, ROIV, INSM: Beneish M-Score Comparison

For the Biotechnology subindustry, Incyte's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Incyte's Beneish M-Score falls into.


WBO:INCY
88GF Score
Incyte Corp WBO:INCY
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Incyte for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0621+0.528 * 1.0019+0.404 * 0.6+0.892 * 1.1248+0.115 * 0.9076
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9099+4.679 * -0.039398-0.327 * 0.6789
=-2.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €910 Mil.
Revenue was 1100.865 + 1286.837 + 1163.815 + 1053.864 = €4,605 Mil.
Gross Profit was 1010.472 + 1183.418 + 1079.467 + 985.544 = €4,259 Mil.
Total Current Assets was €4,744 Mil.
Total Assets was €6,348 Mil.
Property, Plant and Equipment(Net PPE) was €646 Mil.
Depreciation, Depletion and Amortization(DDA) was €81 Mil.
Selling, General, & Admin. Expense(SGA) was €1,185 Mil.
Total Current Liabilities was €1,289 Mil.
Long-Term Debt & Capital Lease Obligation was €25 Mil.
Net Income was 262.38 + 255.584 + 361.392 + 351.134 = €1,230 Mil.
Non Operating Income was -11.834 + -20.587 + 21.134 + 193.034 = €182 Mil.
Cash Flow from Operations was 319.489 + 463.979 + 476.599 + 38.79 = €1,299 Mil.
Total Receivables was €761 Mil.
Revenue was 973.931 + 1125.657 + 1025.222 + 969.652 = €4,094 Mil.
Gross Profit was 906.221 + 1041.139 + 947.736 + 898.491 = €3,794 Mil.
Total Current Assets was €3,244 Mil.
Total Assets was €5,318 Mil.
Property, Plant and Equipment(Net PPE) was €736 Mil.
Depreciation, Depletion and Amortization(DDA) was €83 Mil.
Selling, General, & Admin. Expense(SGA) was €1,157 Mil.
Total Current Liabilities was €1,591 Mil.
Long-Term Debt & Capital Lease Obligation was €30 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(909.547 / 4605.381) / (761.399 / 4094.462)
=0.197497 / 0.185958
=1.0621

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3793.587 / 4094.462) / (4258.901 / 4605.381)
=0.926517 / 0.924766
=1.0019

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4743.885 + 646.015) / 6348.333) / (1 - (3244.364 + 735.607) / 5318.163)
=0.150974 / 0.251627
=0.6

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4605.381 / 4094.462
=1.1248

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(83.169 / (83.169 + 735.607)) / (81.409 / (81.409 + 646.015))
=0.101577 / 0.111914
=0.9076

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1184.578 / 4605.381) / (1157.463 / 4094.462)
=0.257216 / 0.28269
=0.9099

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((25.443 + 1288.546) / 6348.333) / ((30.195 + 1591.268) / 5318.163)
=0.206982 / 0.304892
=0.6789

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1230.49 - 181.747 - 1298.857) / 6348.333
=-0.039398

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Incyte has a M-score of -2.55 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.48 mean?
Incyte (WBO:INCY) has a Beneish M-Score of -2.48 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Incyte and its competitors. According to the industry distribution chart, Incyte ranks #379 out of 831 companies in the Biotechnology industry, placing it in the top 45.6%.
Is Incyte's Beneish M-Score too high?
Incyte's current Beneish M-Score is -2.48. Based on the distribution chart, Incyte ranks #379 out of 831 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Incyte has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Incyte's Beneish M-Score compare to MRNA and ROIV?
According to the Biotechnology industry distribution chart, Incyte ranks #379 out of 831 companies for Beneish M-Score. This puts Incyte in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Incyte and its competitors. Incyte's current Beneish M-Score is -2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Incyte (WBO:INCY) has a current Beneish M-Score of -2.48. The stock's GF Value™ is €65.02, compared to a current price of €70.36 — trading 8.2% above its estimated fair value. The current Beneish M-Score is -2.48. Incyte's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Incyte (WBO:INCY), the current Beneish M-Score is -2.48 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (WBO:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of €70.36 is trading 8.2% above its estimated GF Value™ of €65.02.

Key valuation signals for WBO:INCY:

  • Beneish M-Score: -2.48
  • GF Value™: €65.02 vs. price of €70.36 (8.2% above fair value)
  • GF Score™: 88/100 with 3 warning signs

No single metric tells the full story. See the WBO:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
88GF Score

Get the complete analysis for WBO:INCY

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.36
Price
€65.02
GF Value